Literature DB >> 2039690

Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain.

M J Embleton1, A Charleston, R A Robins, M V Pimm, R W Baldwin.   

Abstract

A bispecific monoclonal antibody recognising both carcinoembryonic antigen (CEA) and ricin toxin A chain (RTA) was tested for its ability to target recombinant RTA (r-RTA) to CEA-expressing tumour cells, alone and in combination with ricin B chain (RTB). The antibody, 636 (Robins et al., 1990), induced significant RTA cytotoxicity against MKN45 gastric carcinoma cells which express high levels of CEA, using the r-RTA at a concentration below that known to be intrinsically cytotoxic. The addition of ricin toxin B chain (RTB) also potentiated cytotoxicity of r-RTA, and there was an additive increase in potentiation against CEA-positive cells when both RTB and 636 were included. The bispecific antibody restored potentiation by RTB after blocking of its binding site with excess galactose, and also the cytotoxic activity of whole ricin which had been blocked with galactose. It was concluded that the 636 bispecific antibody was highly effective in targeting the toxic moiety of the molecule to CEA-expressing cells, and allowed exploitation of the additional ability of the B chain to facilitate cellular incorporation. The facilitating function of the B chain was equally effective whether or not its lectin site was active.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039690      PMCID: PMC1972402          DOI: 10.1038/bjc.1991.153

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

Review 1.  Targeted toxin therapy for the treatment of cancer.

Authors:  D FitzGerald; I Pastan
Journal:  J Natl Cancer Inst       Date:  1989-10-04       Impact factor: 13.506

Review 2.  Receptor-mediated endocytosis.

Authors:  T Wileman; C Harding; P Stahl
Journal:  Biochem J       Date:  1985-11-15       Impact factor: 3.857

3.  Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.

Authors:  L Cattel; L Delprino; P Brusa; F Dosio; P M Comoglio; M Prat
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.

Authors:  K S Webb; S N Liberman; J L Ware; P J Walther
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.

Authors:  M J Glennie; D M Brennand; F Bryden; H M McBride; F Stirpe; A T Worth; G T Stevenson
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

6.  Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.

Authors:  E O Gregg; S H Bridges; R J Youle; D L Longo; L L Houston; M J Glennie; F K Stevenson; I Green
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

7.  Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents.

Authors:  V S Byers; M V Pimm; I Z Pawluczyk; H M Lee; P J Scannon; R W Baldwin
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

8.  Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids.

Authors:  J R Corvalan; W Smith
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA.

Authors:  M R Price; S Edwards; E Jacobs; I Z Pawluczyk; V S Byers; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.

Authors:  M V Pimm; R A Robins; M J Embleton; E Jacobs; A J Markham; A Charleston; R W Baldwin
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

View more
  5 in total

1.  Capture of recombinant ricin A chain by a bispecific anti-RTA:anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice.

Authors:  M V Pimm; R A Robins; R W Baldwin
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.

Authors:  J F Tarlton; D L Easty
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

3.  Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.

Authors:  J Zorzos; D V Skarlos; P Pozatzidou; A Zizi; A Bakiras; S Koritsiadis; D Pectasidis; P Koutsioumba; A A Epenetos; M Likourinas
Journal:  Urol Res       Date:  1994

Review 4.  Targeting Macromolecules to CNS and Other Hard-to-Treat Organs Using Lectin-Mediated Delivery.

Authors:  Walter Acosta; Carole L Cramer
Journal:  Int J Mol Sci       Date:  2020-02-01       Impact factor: 5.923

Review 5.  Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers.

Authors:  Hendrik Fuchs; Alexander Weng; Roger Gilabert-Oriol
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.